sp @11.5c is undervalued considering what is taking shape here:
* 2 X Phase 2 trials underway,
* 1 X Phase 1 trial in collaboration with the leading research organisation near completion,
* 1 X patented technology for topical applications with proven performance,
* 1 X topical antibiotic drug trial at design stage following outstanding third party generated results,
* widening recognition by the world's top leading dermatologists of Botanix' s unique pipeline set.
MC of $87m.....!??....that'd be the potential monthly revenue for just one of the drugs.
sp @11.5c is undervalued considering what is taking shape here:...
-
- There are more pages in this discussion • 228 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 50026 | 4 |
View Market Depth
| Last trade - 09.33am 26/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable
